
The FDA approved the oral SERD giredestrant with everolimus for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer based on phase 3 evERA data.
A 56-Year-Old Female With Recurrent Ovarian Cancer
Case: A 56-Year-Old Female With Recurrent Ovarian Cancer






